中国医学科学院北京协和医学院科技创新十年回眸

doi:10.24920/004167

摘要/Abstract

摘要：

本文从深化科技体制改革、优化科技创新生态方面重点梳理了中国医学科学院北京协和医学院（以下简称“院校”）在医学健康科技创新发展中的改革举措,初步总结了院校近十年来通过科技创新守卫人民健康、推进健康中国战略的亮点工作,主要展示了其在基础研究、疾病防治、医药技术等领域科技创新成果。这些科技成果的取得凸显了院校为实现医学科技自立自强、全面推进健康中国建设提供重要支撑,为我国医学科技事业发展做出重要贡献。

关键词: 中国医学科学院北京协和医学院, 医学健康, 科技创新, 十年

Abstract:

Focusing on the reform initiatives of Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC) in medical scientific and technological innovation from perspectives of deepening the reform and optimizing the ecosystem of science and technology innovation, this article summarizes the highlights of CAMS & PUMC’s efforts in safeguarding people’s health and promoting the Healthy China 2030 strategy through scientific and technological innovation in the fields including basic research, disease prevention and treatment, and medical technology in the past ten years. These achievements embody the endeavors and responsibility of CAMS & PUMC in realizing self-reliance and self-improvement of Chinese medical science and technology and highlight its contributions to the development of medical science and technology of China.

Key words: Chinese Academy of Medical Sciences, Peking Union Medical College, medical health, scientific and technological innovation, ten years

基金资助: 中国医学科学院中央级公益性科研院所基本科研业务费专项资金(2021-ZHL630-003);北京协和医学院中央高校基本科研业务费资助项目(3332022172)

Taolian Yang, Hua Zhong, Wei Wang, Jianwei Wang. A Decade of Scientific and Technological Innovation at Chinese Academy of Medical Sciences & Peking Union Medical College: Retrospect and Prospect[J].Chinese Medical Sciences Journal, 2022, 37(3): 240-45.

参考文献 40.

1.	Chinse Academy of Medical Sciences. Science and Technology Evaluation Metrics. News overview. Available from: http://top100.imicams.ac.cn/news. Accessed: September 30, 2022.
2.	Wang C, Zhai XM, Zhang XQ, et al. Gene-edited babies: Chinese Academy of Medical Sciences’ response and action. The Lancet 2019; 393(10166): 25-6. doi: 10.1016/S0140-6736(18)33080-0. doi: 10.1016/S0140-6736(18)33080-0
3.	Chen K, Liu J, Liu SX, et al. Methyltransferase SETD2-mediated methylation of STAT1 is critical for interferon antiviral activity. Cell 2017; 170(3): 492-506.e14. doi: 10.1016/j.cell.2017.06.042. doi: S0092-8674(17)30761-4 pmid: 28753426
4.	Wang P, Xu JF, Wang YJ, et al. An interferon-independent lncRNA promotes viral replication by modulating cellular metabolism. Science 2017; 358(6366):1051-5. doi: 10.1126/science.aao0409. doi: 10.1126/science.aao0409 pmid: 29074580
5.	Xu XQ, Xu J, Wu JC, et al. Phosphorylation-mediated IFN-γR2 membrane translocation is required to activate macrophage innate response. Cell 2018;175(5):1336-51.e17. doi: 10.1016/j.cell.2018.09.011. doi: S0092-8674(18)31183-8 pmid: 30318148
6.	Jiang MH, Zhang SK, Yang ZH, et al. Self-recognition of an inducible host lncRNA by RIG-I feedback restricts innate immune response. Cell 2018; 173(4): 906-19. doi: 10.1016/j.cell.2018.03.064. doi: S0092-8674(18)30396-9 pmid: 29706547
7.	Han YM, Liu QY, Hou J, et al. Tumor-induced generation of splenic erythroblast-like Ter-Cells promotes tumor progression. Cell 2018; 173(3):634-48.e12. doi: 10.1016/j.cell.2018.02.061. doi: S0092-8674(18)30238-1 pmid: 29606356
8.	Shen QC, Zhang Q, Shi Y, et al. Tet 2 promotes pathogen infection-induced myelopoiesis through mRNA oxidation. Nature 2018; 554(7690):123-7. doi: 10.1038/nature25434. doi: 10.1038/nature25434
9.	Liu Y, You YL, Lu ZK, et al. N6-methyladenosine RNA modification-mediated cellular metabolism rewiring inhibits viral replication. Science 2019; 365(6458):1171-6. doi: 10.1126/science.aax4468. doi: 10.1126/science.aax4468 pmid: 31439758
10.	Wang L, Wen MY, Cao XT. Nuclear hnRNPA2B1 initiates and amplifies the innate immune response to DNA viruses. Science 2019; 365(6454):eaav075. doi: 10.1126/science.aav0758. doi: 10.1126/science.aav0758
11.	Liu YY, Liang XY, Dong WQ, et al. Tumor-repopulating cells induce PD-1 expression in CD8+ T Cells by transferring kynurenine and AhR activation. Cancer Cell 2018; 33(3):480-94.e7. doi: 10.1016/j.ccell.2018.02.005. doi: 10.1016/j.ccell.2018.02.005
12.	Liu YY, Fang YL, Chen XF, et al. Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome. Sci Immunol 2020; 5(43):1-13. doi: 10.1126/sciimmunol.aax7969. doi: 10.1126/sciimmunol.aax7969
13.	Zhou J, Xu JY, Zhang LL, et al. Combined single-cell profiling of lncRNAs and functional screening reveals that H 19 is pivotal for embryonic hematopoietic stem cell development. Cell Stem Cell 2019; 24(2):285-98. doi: 10.1016/j.stem.2018.11.023. doi: S1934-5909(18)30559-9 pmid: 30639035
14.	Dong F, Hao S, Zhang S, et al. Differentiation of transplanted haematopoietic stem cells tracked by single-cell transcriptomic analysis. Nature Cell Biol 2020; 22(6):630-9. doi: 10.1038/s41556-020-0512-1. doi: 10.1038/s41556-020-0512-1
15.	Wang FJ, He JH, Liu SQ, et al. Comprehensive RNA editome reveals that edited Azin 1 partners with DDX1 to enable hematopoietic stem cell differentiation. Blood 2021; 138(20):1939-52. doi: 10.1182/blood.2021011314. doi: 10.1182/blood.2021011314
16.	Li RY, Di L, Li J, et al. A body map of somatic mutagenesis in morphologically normal human tissues. Nature 2021; 597(7876):398-403. doi: 10.1038/s41586-021-03836-1. doi: 10.1038/s41586-021-03836-1
17.	Yang XL, Li JX, Hu DS, et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese population: the China-PAR project (Prediction for ASCVD Risk in China). Circulation 2016; 134(19):1430-40. doi: 10.1161/CIRCULATIONAHA.117.027318. doi: 10.1161/CIRCULATIONAHA.117.027318 pmid: 27682885
18.	Lu XF, Liu ZY, Cui QM, et al. A polygenic risk score improves risk stratification of coronary artery disease: a large-scale prospective Chinese cohort study. Eur Heart J 2022; 43(18):1702-+. doi: 10.1093/eurheartj/ehac093. doi: 10.1093/eurheartj/ehac093 pmid: 35195259
19.	Zhang WL, Zhang SY, Deng Y, et al. Trial of intensive blood-pressure control in older patients with hypertension. New Engl J Med 2021; 385(9):1268-79. doi: 10.1056/NEJMoa2111437. doi: 10.1056/NEJMoa2111437
20.	Huang KY, Liang FC, Yang XL. Long term exposure to ambient fine particulate matter and incidence of stroke BMJ: Bri Med J 2020; 368(8229):59. doi: 10.1136/bmj.16720. doi: 10.1136/bmj.16720
21.	Xu B, Tu SX, Song L, et al. Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial. Lancet 2021; 398(10317): 2149-59. doi: 10.1016/S0140-6736(21)02248-0. doi: 10.1016/S0140-6736(21)02248-0 pmid: 34742368
22.	Xiao D, Chen ZM, Wu SN, et al. Prevalence and risk factors of small airway dysfunction, and association with smoking, in China: findings from a national cross-sectional study. from a national cross-sectional study. The Lancet Respira Med 2020; 8(11):1081-93. doi: 10.1016/S2213-2600(20)30155-7. doi: 10.1016/S2213-2600(20)30155-7
23.	Chen WQ, Zheng RS, Baade P, et al. Cancer Statistics in China, 2015. CA: Cancer J Clin 2016; 66(2):115-32. doi: 10.3322/caac.21338. doi: 10.3322/caac.21338
24.	Zeng HM, Chen WQ, Zheng RS, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries. The Lancet Global Health 2018; 6(5):e555-e567. doi: 10.1016/S2214-109X(18)30127-X. doi: 10.1016/S2214-109X(18)30127-X
25.	Chen WQ, Xia CF, Zheng RS, et al. Disparities by province, age, and sex in site-specific cancer burden attributable to 23 potentially modifiable risk factors in China: a comparative risk assessment. The Lancet Global Health 2019; 7(2):e257-e269. doi: 10.1016/S2214-109X(18)30488-1. doi: 10.1016/S2214-109X(18)30488-1
26.	Zhang JJ, Zhao YQ, Dai Yi, et al. Effectiveness of high-risk human papillomavirus testing for cervical cancer screening in China: a multicenter, open-label, randomized clinical trial. JAMA oncology 2021; 7(2):263-70. doi: 10.1001/jamaoncol.2020.6575. doi: 10.1001/jamaoncol.2020.6575 pmid: 33377903
27.	Ministry of Science and Technology of the People’s Republic of China. 2019 National Science and Technology Progress Award Winning Projects Catalogue. Available from: https://www.most.gov.cn/ztzl/gjkxjsjldh/jldh2019/jldh19jlgg/202001/t20200103_150916.html. Accessed:January 10, 2020.
28	Zhu FC, Meng FY, Li JX, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2013; 381(9882):2024-32. doi: 10.1016/S0140-6736(13)61049-1. doi: 10.1016/S0140-6736(13)61049-1
29.	Li RC, Liu LD, Mo ZJ, et al. An inactivated enterovirus 71 vaccine in healthy children. New Engl J Med 2014; 370(9):829-37. doi: 10.1056/NEJMoa1303224. doi: 10.1056/NEJMoa1303224
30.	Xue J, Chong HH, Zhu YM, et al. Efficient treatment and pre-exposure prophylaxis in rhesus macaques by an HIV fusion-inhibitory lipopeptide. Cell 2021; 185(1):131-44. doi: 10.1016/j.cell.2021.11.032. doi: 10.1016/j.cell.2021.11.032 pmid: 34919814
31.	Ministry of Science and Technology of the People’s Republic of China. 2020 National Science and Technology Progress Award Winning Projects Catalogue. Available from: https://www.most.gov.cn/cxfw/kjjlcx/kjjl2020/202111/t20211103_177782.html. Released:November 2, 2021; accessed: September 10, 2022.
32.	Ministry of Science and Technology of the People’s Republic of China. Catalog of the 2017 National Science and Technology Progress Award Winning Projects. Available from: https://www.most.gov.cn/ztzl/gjkxjsjldh/jldh2017/jldh17jlgg/201801/t20180103_137374.html. Released: January 8, 2018; accessed: September 10, 2022.
33.	Ren LL, Wang YM, Wu ZQ, et al. Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study. Chin Med J 2020; 133(9): 1015-24. doi: 10.1097/CM9.0000000000000722. doi: 10.1097/CM9.0000000000000722
34.	Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern. The Lancet 2020; 395(10223):470-3. doi: 10.1016/S0140-6736(20)30185-9. doi: 10.1016/S0140-6736(20)30185-9
35.	Pang XH, Ren LL, Wu SS, et al. COVID-19 Field Response Group, COVID-19 Laboratory Testing Group. Cold-chain food contamination as the possible origin of COVID-19 resurgence in Beijing. Natl Sci Rev 2020; 7(12):1861-64. doi: 10.1093/nsr/nwaa264. doi: 10.1093/nsr/nwaa264 pmid: 34676083
36.	Wang YM, Zhang DY, Du GH, et al. Remdesivir in adults with severe COVID-19: a randomized, double-blind, placebo-controlled, multicentre trial. The Lancet 2020; 395(10236):1569-78. doi: 10.1016/S0140-6736(20)31022-9. doi: 10.1016/S0140-6736(20)31022-9
37.	Guo L, Wang G, Wang YM, et al. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study. The Lancet Microbe 2022; 3(5): E348-56. doi: 10.1016/S2666-5247(22)00036-2. doi: 10.1016/S2666-5247(22)00036-2
38.	Li L, Zhang W, Hu Yu, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 2020; 324(5): 460-70. doi: 10.1001/jama.2020.10044. doi: 10.1001/jama.2020.10044 pmid: 32492084
39.	He ZY, Ren LL, Yang JT, et al. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study. The Lancet 2021; 397(10279): 1075-84. doi: 10.1016/S0140-6736(21)00238-5. doi: 10.1016/S0140-6736(21)00238-5
40.	Chen SM, Zhang ZJ, Yang JT, et al. Fangcang shelter hospitals: a novel concept for responding to public health emergencies. The Lancet 2020; 395(10232): 1305-14. doi: 10.1016/S0140-6736(20)30744-3. doi: 10.1016/S0140-6736(20)30744-3

优先出版

当期目次

过刊浏览

虚拟专题

作者中心

评阅者中心